A yau TSC Alliance® ta yaba da amincewar Hukumar Abinci da Magunguna ta Amurka (FDA's) na HYFTOR ™, wanda shine farkon maganin da FDA ta amince da shi don angiofibromas na fuska a cikin manya da yara masu shekaru shida ko sama da haka waɗanda ke da ƙwayar sclerosis (TSC) . HYFTOR™, wanda Nobelpharma America, LLC ke ƙera, yana da Matsayin Magungunan Marayu don wannan alamar ta musamman.
"Kungiyar TSC Alliance da gaske tana maraba da wannan zaɓi na maganin angiofibromas," in ji Kari Luther Rosbeck, Shugaba & Shugaba na TSC Alliance. “Tunda sau da yawa suna shafar kamannin mutum kuma suna iya haifar da zubar jini, wannan maganin yana da yuwuwar rage tasirin wannan bayyanar ga manya da yara masu TSC. Muna godiya da sadaukarwar Nobelpharma ga al'ummar TSC."
TSC cuta ce da ba kasafai ake samun ta ba wacce ke haifar da ciwace-ciwacen da ba na kansa ba a kan ko a cikin muhimman gabobin jiki, gami da fata. Angiofibromas da TSC ke haifarwa wasu ƙananan kusoshi ne galibi suna warwatse a fuska ta tsakiya, musamman a kan hanci da kuma kunci, kuma galibi ana tattara su a cikin ramukan da ke gefen hanci. Angiofibromas yawanci karami ne fiye da barkono barkono, amma suna iya girma girma. Suna iya zama masu launin fata, ruwan hoda ko ja. Ana samun Angiofibromas a yawancin mutanen da ke da TSC sama da shekaru 5 kuma suna iya zubar da jini cikin sauƙi. Hakanan suna iya yin illa ga kamanni da kamannin kai, wanda hakan ya sa wasu mutane masu TSC su guje wa yanayin zamantakewa.
"A taron TSC Alliance's 2017 Externally-Leed Patient-Focused Drug Development, mun ji kai tsaye daga mutanen da ke da TSC yadda hadarin zubar da jini ya lalata karfinsu na shiga cikin wasanni masu aiki," in ji Steven L. Roberds, PhD, Babban Jami'in Kimiyya na Kimiyya TSC Alliance, "Muna fatan wannan samfurin zai taimaka wa mutane da yawa su rayu cikin koshin lafiya da farin ciki."
